What is A375 cell line?
Table of Contents
What is A375 cell line?
A375 (ATCC® CRL-1619™) is a human melanoma cell line initiated through explant culture of a solid tumor from a 54-year-old female. The cells are adherent with an epithelial morphology. The cells form tumors following implantation into immunocompromised mice.
What is BRAF mutation in melanoma?
A BRAF mutation is a change in a BRAF gene. That change in the gene can lead to an alteration in a protein that regulates cell growth that could allow the melanoma to grow more aggressively. Approximately half of melanomas carry this mutation and are referred to as mutated, or BRAF positive.
How common is BRAF mutation in melanoma?
Approximately 40-60% of melanomas contain a mutation in the gene that encodes BRAF that leads to constitutive activation of downstream signaling in the MAP kinase pathway. In 80-90% of these cases, the activating mutation consists of the substitution of glutamic acid for valine at amino acid 600 (V600E).
What are AGS cells?
AGS is a cell line exhibiting epithelial morphology that was isolated in 1979 from the stomach tissue of a 54-year-old, White, female patient with gastric adenocarcinoma. Homo sapiens, human. Morphology epithelial Tissue Stomach Disease. Gastric Adenocarcinoma. Applications.
Can BRAF mutation be cured?
As such, they do not (usually) “cure” a cancer, but can sometimes control the growth of a cancer for a significant period of time. BRAF inhibitors are most often used along with medications that inhibit the growth of a tumor at other points in the signaling pathway (such as MEK inhibitors).
Who did Jurkat cells come from?
The Jurkat cell line was established from the peripheral blood of a 14 year old boy by Schneider et al., and was originally designated JM. The line was cloned from cells obtained from Dr. Kendall Smith and are mycoplasma free.
What percentage of melanoma is BRAF positive?
It is estimated that BRAF mutation is present in approximately 50-60% of cutaneous melanomas.
How is BRAF mutation treated?
BRAF Inhibitors for Metastatic Melanoma BRAF inhibitors are drugs that can shrink or slow the growth of metastatic melanoma in people whose tumors have a BRAF mutation. BRAF inhibitors include vemurafenib (Zelboraf®), dabrafenib (Tafinlar®), and encorafenib (Braftovi®).
Do you need to activate Jurkat cells?
Jurkat cels can be activated by exposure to a combination of anti-CD3/anti-CD28 or phytoheamaggutinin (PHA), or the C305 mAb originally developped by Arthur Weiss. IL-2 production should be measured 6 to 12 h later (whatever works best for you). 0.5 to 2 millions cells per ml works. We have used the Jurkat E6.
